Center for Cancer Immunotherapy and Immunobiology

  1. Home
  2. Research
  3. Research Divisions, Labs & Researchers
  4. Professor Masakazu Toi

Professor Masakazu Toi
Visiting Professor

Education

  • 1982: M.D., Hiroshima University School of Medicine
  • 1988: Ph.D., Hiroshima University, Medical Science

Professional Experience

  • 1990: Clinical Oncology, ICRF Laboratories, Institute of Molecular Medicine, John-Radcliffe Hospital of Oxford University
  • 1992: Department of Surgery / Division of Clinical Trials and Research, Tokyo Metropolitan Komagome Hospital (2002~ Director）
  • 2000: Department of Breast Medical Oncology, Dana-Farber Cancer Institute of Harvard University as a Yamagiwa-Yoshida Fellow, UICC
  • 2003: Visiting Professor, Hong Kong University; Visiting Professor, DDS Center, School of Pharmacy, Tokyo University of Science
  • 2007: Professor, Breast Surgery, Graduate School of Medicine, Kyoto University, Director, Breast Surgery, Kyoto University Hospital
  • 2016: Vice Director, Office of Society-Academia Collaboration for Innovation (SACI), Kyoto University
  • 2023~: Director, Tokyo Metropolitan Komagome Hospital (Tokyo Metropolitan Cancer and Infectious Disease Center)
  • 2024: Visiting Professor, Zhejiang Cancer Center; Visiting Professor, Nanjing Medical University; Visiting Professor, Center for Cancer Immunotherapy and Immunobiology (CCII)

Research Focus

Development of predictive factors for the effectiveness of preoperative immunochemotherapy

For primary breast cancer patients, we will analyze factors related to the effectiveness and resistance of preoperative immunochemotherapy and develop a prediction system. We will proceed by integrating molecular, histopathological, and imaging factors.

Development of drug therapies, including new immunotherapy

We will proceed with an approach that will enhance the effectiveness of immunotherapy and overcome resistance. We will develop various combination therapies with immunotherapy and analyze immune memory.

Development of clinical systems that enable early detection, appropriate evaluation, and response to treatment-related toxicity

Honors & Awards

Board Member & Membership in Academic Societies

Past

Current

Selected Publications

Nishimura T, Velaga R, Masuda N, Kawaguchi K, Kawaguchi S, Takada M, Maeshima Y, Tanaka S, Kikawa Y, Kadoya T, Bando H, Nakamura R, Yamamoto Y, Ueno T, Yasojima H, Ishiguro H, Morita S, Ohno S, Haga H, Matsuda F, Ogawa S, Toi M. Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors. Cancer Sci. 2024 Dec;115(12):3928-3942. DOI: 10.1111/cas.16339. Epub 2024 Oct 7.

Maeshima Y, Kataoka TR, Vandenbon A, Hirata M, Takeuchi Y, Suzuki Y, Fukui Y, Kawashima M, Takada M, Ibi Y, Haga H, Morita S, Toi M, Kawaoka S, Kawaguchi K. Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals the reduction of CD169(+) macrophages by metastatic breast cancers. EBioMedicine. 2024 Sep;107:105271. DOI: 10.1016/j.ebiom.2024.105271. Epub 2024 Aug 21. PMID: 39173531; PMCID: PMC11382037.

Toi M, Kinoshita T, Benson JR, Jatoi I, Kataoka M, Han W, Yamauchi C, Inamoto T, Takada M. Non-surgical ablation for breast cancer: an emerging therapeutic option. Lancet Oncol. 2024 Mar;25(3):e114-e125. DOI: 10.1016/S1470-2045(23)00615-0.

Saldajeno DP, Kawaoka S, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga RM, Tamura N, Aruga T, Ikeda K, Fukui Y, Maeshima Y, Takada M, Suzuki E, Ueno T, Ogawa S, Haga H, Ohno S, Morita S, Kawaguchi K, Toi M. Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients. Br J Cancer. 2024 Apr;130(6):1023-1035. DOI: 10.1038/s41416-023-02527-0. Epub 2024 Jan 18.

Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, Llombart-Cussac A, Kaufman PA, Toi M, Jerusalem G, Graham H, Wang H, Jansen VM, Litchfield LM, Martin M. Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer. Clin Cancer Res. 2024 May 15;30(10):2233-2244. DOI: 10.1158/1078-0432.CCR-22-3573.

WordPress Lightbox